AstraZeneca has said that a trio of lawsuits filed by Bristol-Myers Squibb and Ono Pharma alleging patent infringement with its checkpoint inhibitor drugs Imjudo and Imfin
Bristol-Myers Squibb is facing some serious near-term challenges as its top-selling drugs come under pressure, forcing it to slash its sales forecasts for the year.
Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica
Just a few weeks after its approval in the UK, Bristol-Myers Squibb’s new oral psoriasis therapy Sotyktu has been recommended for routine NHS in England and Wales.
Bristol-Myers Squibb has filed a lawsuit against the US government that aims to block the drug price negotiation elements of the Inflation Reduction Act (IRA), joining fel
Seagen’s Adcetris was trounced by Bristol-Myers Squibb’s Opdivo in a head-to-head trial in classical Hodgkin lymphoma (cHL) reported at ASCO – but there may be a way for t